Why the study?
Recent data indicated a potential benefit of GLP-1 RAs on kidney disease progression in CKD, prompting an evaluation of their effect on worsening kidney function across different populations.
Do GLP-1 RAs reduce worsening kidney function in patients with type 2 diabetes or overweight/obesity?
Do GLP-1 RAs reduce worsening kidney function in patients with type 2 diabetes or overweight/obesity?
GLP-1 RAs significantly reduce the risk of kidney disease progression in patients with type 2 diabetes or overweight/obesity, regardless of baseline CKD status.
No takes yet. Share an insight, caveat, or question.
GLP-1 RAs merit consideration to reduce kidney outcomes in T2D or obesity; extends RCT evidence across CKD status.
Mendonça et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: